STSA
Income statement / Annual
Last year (2022), Satsuma Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Satsuma Pharmaceuticals, Inc.'s net income was -$69.16 M.
See Satsuma Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$44.09 M
|
$37.64 M
|
$36.27 M
|
$24.20 M
|
$6.43 M
|
$4.19 M
|
| General & Administrative Expenses |
$15.13 M
|
$13.53 M
|
$12.06 M
|
$4.69 M
|
$1.08 M
|
$754.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.13 M
|
$13.53 M
|
$12.06 M
|
$4.69 M
|
$1.08 M
|
$754.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$1.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$59.22 M
|
$51.17 M
|
$48.33 M
|
$28.88 M
|
$7.52 M
|
$4.95 M
|
| Cost And Expenses |
$59.22 M
|
$51.17 M
|
$48.33 M
|
$28.88 M
|
$7.52 M
|
$4.95 M
|
| Interest Income |
$905.00 K
|
$157.00 K
|
$1.12 M
|
$1.19 M
|
$72.00 K
|
$30.00 K
|
| Interest Expense |
$13.00 K
|
$163.00 K
|
$350.00 K
|
$482.00 K
|
$90.00 K
|
$15.00 K
|
| Depreciation & Amortization |
$12.63 M
|
$550.00 K
|
$1.12 M
|
$1.19 M
|
$57.00 K
|
$10.00 K
|
| EBITDA |
-$58.31 M |
-$50.62 M |
-$46.10 M |
-$26.51 M |
-$7.20 M |
-$5.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$892.00 K
|
-$6.00 K
|
$765.00 K
|
$706.00 K
|
$169.00 K
|
-$225.00 K
|
| Income Before Tax |
-$70.06 M
|
-$51.17 M
|
-$47.56 M
|
-$28.18 M
|
-$7.35 M
|
-$5.17 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$892.00 K
|
$92.00 K
|
$111.00 K
|
$340.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$69.16 M
|
-$51.26 M
|
-$47.67 M
|
-$28.52 M
|
-$7.35 M
|
-$5.17 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.16 |
-1.76 |
-2.74 |
-4.86 |
-1.86 |
-0.76 |
| EPS Diluted |
-2.16 |
-1.76 |
-2.74 |
-4.86 |
-1.86 |
-0.76 |
| Weighted Average Shares Out |
$32.02 M
|
$29.17 M
|
$17.41 M
|
$5.86 M
|
$3.94 M
|
$6.80 M
|
| Weighted Average Shares Out Diluted |
$32.02 M
|
$29.17 M
|
$17.41 M
|
$5.86 M
|
$3.94 M
|
$6.80 M
|
| Link |
|
|
|
|
|
|
